In hepatocellular carcinoma (HCC) patients from GSE140901 dataset, the proportion of high senescence signature of the group with clinical benefit response after anti-PD-1/anti-PD-L1-based therapy was significantly lower than the group without clinical benefit (Fig. 6C, P = 0.068). The gene discussed is CD274; the disease is hepatocellular carcinoma.